These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11132039)

  • 1. Mechanisms of mesangial injury in glomerular diseases.
    Daha MR
    J Nephrol; 2000; 13 Suppl 3():S89-95. PubMed ID: 11132039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The humoral and cellular factors of glomerular damage].
    Camussi G; Montrucchio G
    Ann Ital Med Int; 1992; 7(4):226-33. PubMed ID: 1298333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circumferential mesangial interposition: a form of mesangiolysis.
    Nakamoto Y; Yasuda T; Imai H; Miura AB
    Nephrol Dial Transplant; 1992; 7(5):373-8. PubMed ID: 1321370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glomerular regeneration is delayed in nephritic alpha 8-integrin-deficient mice: contribution of alpha 8-integrin to the regulation of mesangial cell apoptosis.
    Hartner A; Marek I; Cordasic N; Haas C; Schocklmann H; Hulsmann-Volkert G; Plasa I; Rascher W; Hilgers KF; Amann K
    Am J Nephrol; 2008; 28(1):168-78. PubMed ID: 17951999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model).
    Jefferson JA; Johnson RJ
    J Nephrol; 1999; 12(5):297-307. PubMed ID: 10630692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice.
    Pérez De Lema G; De Wit C; Cohen CD; Nieto E; Molina A; Banas B; Luckow B; Vicente AB; Mampaso F; Schlöndorff D
    J Pharmacol Exp Ther; 2003 Oct; 307(1):275-81. PubMed ID: 12954793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mesangial glomerulonephritis and intermediate uveitis].
    Román E; Zamora I; Vera F
    Nefrologia; 2004; 24(5):489-92. PubMed ID: 15648908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Arthus-type nephritis and glomerular clearing system].
    Ishigame H
    Nihon Jinzo Gakkai Shi; 1991 Feb; 33(2):105-18. PubMed ID: 2051636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights in the pathogenesis of IgA nephropathy.
    Monteiro RC
    Nefrologia; 2005; 25 Suppl 2():82-6. PubMed ID: 16050408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches.
    Gómez-Guerrero C; Hernández-Vargas P; López-Franco O; Ortiz-Muñoz G; Egido J
    Curr Drug Targets Inflamm Allergy; 2005 Jun; 4(3):341-51. PubMed ID: 16101544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of atherogenic lipoproteins in cytokine-mediated renovascular injury.
    Kirschenbaum MA; Pai R; Roh DD; Kamanna VS
    Miner Electrolyte Metab; 1996; 22(1-3):47-50. PubMed ID: 8676823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of renal sarcoidosis with complement activation via the lectin pathway.
    Hagiwara S; Ohi H; Eishi Y; Kodama F; Tashiro K; Makita Y; Suzuki Y; Maeda K; Fukui M; Horikoshi S; Tomino Y
    Am J Kidney Dis; 2005 Mar; 45(3):580-7. PubMed ID: 15754281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune complex degradation by cultured rat mesangial cells.
    Furness PN
    J Pathol; 1993 Jun; 170(2):197-203. PubMed ID: 8345409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy.
    Chan LY; Leung JC; Tang SC; Choy CB; Lai KN
    J Am Soc Nephrol; 2005 Aug; 16(8):2306-17. PubMed ID: 15930094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The many effects of complement C3- and C5-binding proteins in renal injury.
    Puri TS; Quigg RJ
    Semin Nephrol; 2007 May; 27(3):321-37. PubMed ID: 17533009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-kappaB-mediated expression in cultured human mesangial cells.
    Tsukinoki T; Sugiyama H; Sunami R; Kobayashi M; Onoda T; Maeshima Y; Yamasaki Y; Makino H
    Clin Exp Nephrol; 2004 Sep; 8(3):196-205. PubMed ID: 15480896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis.
    Uchimura H; Marumo T; Takase O; Kawachi H; Shimizu F; Hayashi M; Saruta T; Hishikawa K; Fujita T
    J Am Soc Nephrol; 2005 Apr; 16(4):997-1004. PubMed ID: 15744001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological intervention in renal fibrosis and vascular sclerosis.
    Becker GJ; Perkovic V; Hewitson TD
    J Nephrol; 2001; 14(5):332-9. PubMed ID: 11730265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient with diffuse mesangial and endocapillary proliferative glomerulonephritis with hypocomplementemia and elevated anti-streptolysin O treated with prednisolone, angiotensin-converting enzyme inhibitor, and angiotensin II receptor antagonist.
    Ito S; Kuriyama H; Iino N; Iguchi S; Shimada H; Ueno M; Narita I; Nakano M; Nishi S; Karasawa R; Gejyo F
    Clin Exp Nephrol; 2003 Dec; 7(4):290-5. PubMed ID: 14712359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipids and the progression of renal disease.
    Keane WF; O'Donnell MP; Kasiske BL; Schmitz PG
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S69-74. PubMed ID: 16989069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.